Fig. 1: XBB.1.5 monovalent vaccination boosts antibody responses. | Communications Medicine

Fig. 1: XBB.1.5 monovalent vaccination boosts antibody responses.

From: Immune imprinting and vaccine interval determine antibody responses to monovalent XBB.1.5 COVID-19 vaccination

Fig. 1

a Pre- and post-XBB.1.5 vaccination sera were collected from healthcare workers who previously received the bivalent vaccine or not. Live SARS-CoV-2 neutralization by serum antibodies was assessed by focus reduction neutralization test (FRNT) and reported as FRNT50s for bivalent recipients (b) and non-recipients (c). Serum antibody isotype titers against ancestral spike RBD were determined by enzyme-linked immunosorbent assay (ELISA) and reported as EC50 for bivalent recipients (d) and non-recipients (e). The dotted lines indicate assay lower limits of detection. Geometric mean titers (GMT) for each bar were calculated in GraphPad Prism. Fold changes were calculated by dividing the post-XBB.1.5 vaccination titer by pre-vaccination titer. Reported p-values are the result of a one-way repeated measures ANOVA (b, c) or restricted maximum likelihood model (d, e) with Holm-Sidak multiple comparisons correction for pairwise comparisons between variant-specific and isotype titers within the bivalent recipient (n = 30) or non-recipient (n = 10) groups.

Back to article page